Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) has reported its financial results for the first quarter ended March 31, 2025. The company's net revenue for Q1 2025 was $695 million, showing a 5% increase compared to the same period in 2024, when it was $659 million.
The Affordable Medicines segment experienced a 6% increase in net revenue, attributed to the strong performance of the complex product portfolio and new product launches. The Specialty segment also saw a 3% increase in net revenue driven by key branded products, including Crexont® and Unithroid®. Additionally, the AvKARE segment's net revenue increased by 6%, propelled by growth in the government label sales channel.
In terms of net income, Amneal reported $12 million for Q1 2025, a significant improvement from a net loss of $92 million in Q1 2024. This positive shift was influenced by higher revenue and gross profit, as well as a legal settlement charge of $94 million in the first quarter of 2024.
The company's adjusted EBITDA for the first quarter of 2025 was $170 million, marking a 12% increase from the first quarter of 2024. This growth is attributed to strong revenue performance, higher gross margin, and operating expense leverage.
Diluted income per share for Q1 2025 was $0.04, a notable improvement from diluted loss per share of $0.30 for Q1 2024, driven by higher operating income and lower interest expense. Adjusted diluted earnings per share in Q1 2025 were $0.21, indicating a 50% increase from $0.14 for the same period in 2024.
Amneal Pharmaceuticals, Inc. has also affirmed its 2025 full-year guidance, expressing confidence in its ability to deliver sustainable growth and value creation for its stakeholders. The market has reacted to these announcements by moving the company's shares -0.6% to a price of $7.69. For more information, read the company's full 8-K submission here.
